This trial is no longer available!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Ewing Sarcoma
and you are
between 48 and 50
years old
The phase for this study is not defined.
Show me locations

The purpose

Despite improvements in outcomes for patients with localized Ewing sarcoma, patients with relapsed metastatic Ewing sarcoma continue to have poor outcomes with current chemotherapy options. A large body of preclinical data supports a role for IGF-1R inhibition in the treatment of Ewing sarcoma. More recently, clinical trials of IGF-1R monoclonal antibodies have demonstrated single- agent activity in patients with relapsed Ewing sarcoma. Ganitumab (AMG 479) is a fully human monoclonal antibody directed against IGF-1R. We are proposing this single-agent expanded access IND to provide our patient the opportunity to benefit from this treatment after having developed progressive disease after multiple lines of prior therapy.

Provided treatments

  • Drug: Ganitumab

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029481. The sponsor of the trial is Jonsson Comprehensive Cancer Center and it is looking for 0 volunteers for the current phase.
Official trial title:
Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma